Literature DB >> 8615043

NF-kappaB activation Is delayed in mouse L929 cells infected with interferon suppressing, but not inducing, vesicular stomatitis virus strains.

A H Boulares1, M C Ferran, J Lucas-Lenard.   

Abstract

Vesicular stomatitis virus (VSV) mutant T1026R1 of the Indiana (IN) serotype is a good inducer of interferon (IFN). This mutant was used to study the activation of NF-kappaB, a transcription factor necessary for IFN induction, in mouse L929 cells that were stably transfected with a chimeric gene containing the human IFN-beta gene promoter attached to the chloramphenicol acetyltransferase (CAT) coding sequence. NF-kappaB DNA binding activity was detected as early as 30 min after virus adsorption in nuclear extracts, increased up to 4 hr, and then remained constant for at least 6 additional hr. The kinetics of CAT expression correlated with the kinetics of NF-kappaB nuclear DNA binding activity. Virus entry and delivery of viral components into the cytoplasm were required for NF-kappaB activation. Exposure of T1026R1 to one hit of UV irradiation nearly completely reduced NF-kappaB activation. In cells infected with wild-type (wt) VSV (IN), a noninducer of IFN, NF-kappaB DNA binding activity in the nucleus was delayed for several hours after virus adsorption. Coinfection of wt VSV and T1026R1 resulted in the reduction of T1026R1-promoted NF-kappaB activation. This inhibitory activity of wt VSV was abolished by one hit of UV irradiation. Under similar conditions expression of the CAT gene was more UV resistant, suggesting that IFN gene expression is regulated at multiple levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615043     DOI: 10.1006/viro.1996.0167

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

Review 1.  Cytopathogenesis and inhibition of host gene expression by RNA viruses.

Authors:  D S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  The protein kinase PKR: a molecular clock that sequentially activates survival and death programs.

Authors:  Olivier Donzé; Jing Deng; Joseph Curran; Robert Sladek; Didier Picard; Nahum Sonenberg
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

3.  The vesicular stomatitis virus matrix protein inhibits NF-κB activation in mouse L929 cells.

Authors:  Andrew J Varble; Christopher D Ried; Warren J Hammond; Kaitlin A Marquis; Matthew C Woodruff; Maureen C Ferran
Journal:  Virology       Date:  2016-09-17       Impact factor: 3.616

4.  Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism.

Authors:  Ana L Abujamra; Remco A Spanjaard; Idowu Akinsheye; Xiansi Zhao; Douglas V Faller; Sajal K Ghosh
Journal:  Virology       Date:  2005-11-14       Impact factor: 3.616

5.  Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis.

Authors:  Maryam Ahmed; Margie O McKenzie; Shelby Puckett; Michael Hojnacki; Laurent Poliquin; Douglas S Lyles
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter.

Authors:  M C Ferran; J M Lucas-Lenard
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Interferon induction as a quasispecies marker of vesicular stomatitis virus populations.

Authors:  P I Marcus; L L Rodriguez; M J Sekellick
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.

Authors:  Bo Chen; Qin Zong; Ricardo Cibotti; Chad Morris; Juana Castaneda; Brian Naiman; Derong Liu; Anna Glodek; Gary P Sims; Ronald Herbst; Stephen K Horrigan; Peter A Kiener; Dan Soppet; Anthony J Coyle; Laurent Audoly
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

9.  Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.

Authors:  Mohamed A Ghonim; Salome V Ibba; Abdelmetalab F Tarhuni; Youssef Errami; Hanh H Luu; Matthew J Dean; Ali H El-Bahrawy; Dorota Wyczechowska; Ilyes A Benslimane; Luis Del Valle; Amir A Al-Khami; Augusto C Ochoa; A Hamid Boulares
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.